Brief: Invex Therapeutics Announces Granting Of Orphan Drug Designation For Exenatide
23/06/2023 01:36
June 23 (Reuters) - Invex Therapeutics Ltd IXC.AX :
* GRANTING OF ORPHAN DRUG DESIGNATION FOR EXENATIDE IN
TREATMENT
OF MODERATE TO SEVERE TRAUMATIC BRAIN INJURY
* GRANTING OF ORPHAN DRUG DESIGNATION FROM EUROPEAN
MEDICINES
AGENCY
Source text for Eikon: ID:nASX4PdmvS
Further company coverage: IXC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invex Therapeutics
See all newsBrief: Invex Therapeutics Requests Trading Halt
Brief: Invex Therapeutics Says Narelle Warren Resigns As CFO
Brief: Invex Therapeutics' Negotiations Discontinued With Neurological Disease Therapeutics Development Co
Australia's Invex Therapeutics falls as agreement talks fade
Brief: Invex Therapeutics Seeks Trading Halt